journal article·2026-04Open access

Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles

Jiaxin Yu, Chaojie Zhu, Hongjun Li, Feng Xu

Abstract

Cancer vaccination requires effective integration of antigen delivery and immune activation across secondary lymphoid organs and tumor tissues, yet many conventional adjuvants rely on static molecular or material-based cues that are poorly aligned with dynamic antitumor immune processes. To address this gap, the concept of living adjuvants has emerged to describe biologically active systems that enhance vaccination by actively participating in immune regulation rather than serving as passive stimulatory components. While the broader concept may include microorganisms, we focus exclusively on endogenous living adjuvants, defined as self-derived cellular systems, including dendritic cells, red blood cells, B cells, mesenchymal stromal cells, and tumor cells, which share key features such as physiological trafficking, sustained cellular interactions, and amenability to chemical or genetic engineering, enabling integrated immune modulation within a single platform. We define the core concepts and mechanisms underlying endogenous living adjuvants, summarize representative strategies, and discuss design principles that govern their effectiveness, controllability, safety, and translational potential. This review provides a unified framework to guide the rational engineering of endogenous living adjuvants, ultimately informing the development of next-generation cancer immunotherapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Recent advances in therapeutic cancer vaccines10.1038/s41568-025-00820-z ↗
2. Therapeutic cancer vaccines10.1038/s41568-021-00346-0 ↗
3. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
4. Cancer vaccines: the next immunotherapy frontier10.1038/s43018-022-00418-6 ↗
5. Sipuleucel-T immunotherapy for castration-resistant prostate cancer10.1056/NEJMoa1001294 ↗
6. Therapeutic cancer vaccines10.1172/JCI80009 ↗
7. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines10.1038/nrc2373 ↗
8. Therapeutic cancer vaccines: advancements, challenges and prospects10.1038/s41392-023-01674-3 ↗
9. Enhancing immune responses to tumor-associated antigens10.4161/cbt.8.15.9133 ↗
10. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy10.1038/nrc3670 ↗
11. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer10.1038/nature23003 ↗
12. An immunogenic personal neoantigen vaccine for patients with melanoma10.1038/nature22991 ↗
13. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments10.3389/fimmu.2020.615240 ↗
14. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns10.1038/nri2868 ↗
15. Designing spatial and temporal control of vaccine responses10.1038/s41578-021-00372-2 ↗
16. Recent advances in the discovery and delivery of vaccine adjuvants10.1038/nrd1176 ↗
17. Vaccine adjuvants: putting innate immunity to work10.1016/j.immuni.2010.10.002 ↗
18. Vaccine adjuvants: mechanisms and platforms10.1038/s41392-023-01557-7 ↗
19. Vaccine adjuvants: tailoring innate recognition to send the right message10.1016/j.immuni.2024.03.015 ↗
20. Engineering new approaches to cancer vaccines10.1158/2326-6066.CIR-15-0112 ↗
21. Cell and tissue engineering in lymph nodes for cancer immunotherapy10.1016/j.addr.2020.07.023 ↗
22. Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
23. Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis10.1111/irv.12871 ↗
24. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women10.1016/S0140-6736(09)61248-4 ↗
25. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial10.1016/S1470-2045(16)00099-1 ↗
26. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial10.1016/S1470-2045(18)30254-7 ↗
27. Delivering living medicines with biomaterials10.1038/s41578-024-00766-y ↗
28. Engineered bacteria for augmented In situ tumor vaccination10.1039/D2BM01593E ↗
29. Therapy with oncolytic viruses: progress and challenges10.1038/s41571-022-00719-w ↗
30. Enhancing in situ cancer vaccines using delivery technologies10.1038/s41573-024-00974-9 ↗
31. B cells and tertiary lymphoid structures promote immunotherapy response10.1038/s41586-019-1922-8 ↗
32. Nanovaccine's rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy10.1016/j.nantod.2020.100923 ↗
33. Two-dimensional layered double hydroxide nanoadjuvant: recent progress and future direction10.1039/D1NR00881A ↗
34. Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy10.1016/j.biomaterials.2018.05.015 ↗
35. Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS0110.1038/srep39475 ↗
36. CD169+ macrophages capture and dendritic cells instruct: the interplay of the gatekeeper and the general of the immune system10.3389/fimmu.2018.02472 ↗
37. Regulation of dendritic cell migration to the draining lymph node10.1084/jem.20030448 ↗
38. Targeted modulation of immune cells and tissues using engineered biomaterials10.1038/s44222-022-00016-2 ↗
39. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes10.1073/pnas.0610383104 ↗
40. Engineering nanomaterial physical characteristics for cancer immunotherapy10.1038/s44222-023-00047-3 ↗
41. Compartmentalization of dendritic cell and t‐cell interactions in the lymph node: anatomy of t‐cell fate decisions10.1111/imr.12758 ↗
42. Structure and function of the immune system in the spleen10.1126/sciimmunol.aau6085 ↗
43. Differential intrasplenic migration of dendritic cell subsets tailors adaptive immunity10.1016/j.celrep.2016.07.076 ↗
44. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy10.1038/nature18300 ↗
45. Immune adjuvant effect of molecularly-defined toll-like receptor ligands10.3390/vaccines2020323 ↗
46. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy10.1093/annonc/mdx237 ↗
47. Cancer vaccines as enablers of immunotherapy10.1038/s41590-025-02308-2 ↗
48. Cross-priming in cancer immunology and immunotherapy10.1038/s41568-024-00785-5 ↗
49. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer10.1038/s41586-023-06063-y ↗
50. Dendritic cell maturation and cross‐presentation: timing matters10.1111/imr.12432 ↗
51. In situ vaccination as a strategy to modulate the immune microenvironment of hepatocellular carcinoma10.3389/fimmu.2021.650486 ↗
52. In situ vaccination: cancer immunotherapy both personalized and off‐the‐shelf10.1016/j.molonc.2015.10.016 ↗
53. A peritumorally injected immunomodulating adjuvant elicits robust and safe metalloimmunotherapy against solid tumors
54. Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors10.1038/s41392-024-02028-3 ↗
55. Radiotherapy and immunotherapy for cancer: from “Systemic” to “Multisite,”10.1158/1078-0432.CCR-19-2034 ↗
56. Damage-associated molecular patterns in cancer: a double-edged sword10.1038/onc.2016.104 ↗
57. Efficient immunotherapy of drug-free layered double hydroxide nanoparticles via neutralizing excess acid and blocking tumor cell autophagy10.1021/acsnano.2c02183 ↗
58. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
59. Immunogenicity of necrotic cell death10.1007/s00018-014-1741-x ↗
60. Oxygen in the tumor microenvironment: effects on dendritic cell function10.18632/oncotarget.26608 ↗
61. Control of dendritic cell function within the tumour microenvironment10.3389/fimmu.2022.733800 ↗
62. Tumor-draining lymph nodes: at the crossroads of metastasis and immunity10.1126/sciimmunol.abg3551 ↗
63. Dendritic cells as shepherds of T cell immunity in cancer10.1016/j.immuni.2023.08.014 ↗
64. Intratumoral immunotherapy: using the tumor as the remedy10.1093/annonc/mdx683 ↗
65. Key roles of adjuvants in modern vaccines10.1038/nm.3409 ↗
66. Emerging concepts in the science of vaccine adjuvants10.1038/s41573-021-00163-y ↗
67. Engineering cells for therapy and diagnosis10.1038/s44222-024-00198-x ↗
68. Dendritic cells and the control of immunity10.1038/32588 ↗
69. Mannose receptor‐mediated uptake of antigens strongly enhances HLA class II‐restricted antigen presentation by cultured dendritic cells10.1002/eji.1830270942 ↗
70. Mature dendritic cells use endocytic receptors to capture and present antigens10.1073/pnas.0910609107 ↗
71. Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration10.1039/C9RA00818G ↗
72. Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists10.1177/1758834010397692 ↗
73. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine10.1158/1078-0432.CCR-10-3126 ↗
74. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer10.1007/s00262-012-1317-2 ↗
75. Nanomodulators targeting tumor-resident immunosuppressive cells: mechanisms and recent updates10.1016/j.nantod.2022.101641 ↗
76. Dendritic-cell-based therapeutic cancer vaccines10.1016/j.immuni.2013.07.004 ↗
77. Dendritic cell-based immunotherapy10.1038/cr.2016.157 ↗
78. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells10.1186/s40425-019-0580-6 ↗
79. Evaluation of in vivo labelled dendritic cell migration in cancer patients10.1186/1479-5876-2-27 ↗
80. Magnetic enrichment of dendritic cell vaccine in lymph node with fluorescent-magnetic nanoparticles enhanced cancer immunotherapy10.7150/thno.15102 ↗
81. Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions10.1126/sciadv.abb6595 ↗
82. A lymph node-targeted cell-nanoadjuvant conjugate enhances dendritic cell-T cell crosstalk for cancer immunotherapy10.1016/j.apsb.2025.12.032 ↗
83. A dendritic cell‐nanogel conjugate for tumor‐draining lymph node‐specific PD‐L1 blockade10.1002/adma.202504733 ↗
84. Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine10.1038/s41467-023-40886-7 ↗
85. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients10.1038/mt.2012.11 ↗
86. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients10.1093/annonc/mdt245 ↗
87. Vaccination with mRNA-Electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients10.1158/1078-0432.CCR-11-3368 ↗
88. Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but not sec61 and/or Derlin-110.1371/journal.pone.0089897 ↗
89. mRNA-transfected dendritic cells expressing polypeptides that link MHC-I presentation to constitutive TLR4 activation confer tumor immunity10.1038/mt.2015.90 ↗
90. Cancer immunotherapy using RNA-loaded dendritic cells10.1046/j.1365-2249.2003.02286.x ↗
91. Engineering dendritic cells to enhance cancer immunotherapy10.1038/mt.2011.57 ↗
92. The clinical progress of mRNA vaccines and immunotherapies10.1038/s41587-022-01294-2 ↗
93. Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects10.1038/s41571-023-00811-9 ↗
94. Fluorinated lipid nanoparticles for enhancing mRNA delivery efficiency10.1021/acsnano.3c04507 ↗
95. Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system10.1186/s12943-025-02480-x ↗
96. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation10.1007/s00262-012-1334-1 ↗
97. Lipid nanoparticle-mediated mRNA/siRNA dual-bioengineered dendritic cell vaccines combined of PD-1/PD-L1 blockade for boosting tumor immunotherapy
98. Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization10.1038/s41467-025-59840-w ↗
99. In situ antigen-capture strategies for enhancing dendritic cell-mediated anti-tumor immunity10.1016/j.jconrel.2025.113984 ↗
100. Follicular helper T cells as cognate regulators of B cell immunity10.1016/j.coi.2009.05.010 ↗